Drug Profile
Budesonide/salbutamol - Avillion/Pearl Therapeutics
Alternative Names: AIRSUPRA; Albuterol/budesonide - Avillion/Pearl Therapeutics; BDA MDI/PT027; PT-027Latest Information Update: 18 Mar 2024
Price :
$50
*
At a glance
- Originator Pearl Therapeutics
- Developer AstraZeneca; Avillion
- Class Anti-inflammatories; Antiallergics; Antiasthmatics; Antibronchitics; Bronchodilators; Ethanolamines; Glucocorticoids; Phenethylamines; Pregnenediones; Small molecules; Tocolytics
- Mechanism of Action Beta 2 adrenergic receptor agonists; Glucocorticoid receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Asthma
Most Recent Events
- 13 Mar 2024 AstraZeneca plans a phase IIIb ACADIA trial in Asthma (In adolescents, In children) (Inhalation) in March 2024 (NCT06307665)
- 22 Jan 2024 Launched for Asthma (In the elderly, In adults) in USA (Inhalation)
- 22 Dec 2023 Phase-III clinical trials in Asthma (Treatment-experienced, In adults, In the elderly) in Russia (Inhalation) (NCT06245551)